We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Waters Corp. (WAT - Free Report) recently inked an agreement with Andrew Alliance, which will enable drug development scientists to access a semi-automated sample preparation approach for released N-glycan profiling and analysis by LC and LC-MS.
Per the agreement, Waters Corp. will integrate its existing Glycoworks RapiFluor-MS (RFMS) N-Glycan Kits with an Andrew pipetting robot. A huge number of protein therapeutics are presently in development, and consequently the demand for glycan analyses is growing exponentially. Thus, this semi-automated sample preparation approach will enable laboratories to cater to the huge demand for glycan profiling, with better accuracy and precision of LC and LC-MS results.
Biopharmaceutical companies, these days, need to deliver detailed structural information on glycans for regulatory approval. Since its launch in Feb 2015, RFMS N-Glycan Kit has benefited laboratories by providing simplified sample preparation at unprecedented speed and sensitivity. The combination of Waters and Andrew Alliance technologies makes it simpler and more efficient to scale up samples tested with the same enhanced optical, and MS sensitivity that users got the RapiFluor-MS labelling reagent.
Waters Corp. has been riding on strong momentum in its pharmaceutical business. Positive macro trends, including rising global regulatory standards, increasing access of patients to prescription drugs, growing testing needs of newer biological drugs and ever-increasing complexity in molecular structure, are acting as tailwinds for the pharmaceutical business. Its solid presence in the chromatography instrument and pharmaceuticals markets should generate enhanced profits, going forward.
The company recent share price performance also reflects these robust growth trends. Over the past six months, shares of Water Corp. recorded an average return of 35.9%, ahead of the Zacks Classified Instruments-Scientific industry average of 30%.
The analyst community is also feeling bullish about this Zacks Rank #2 (Buy) company as its earnings estimates continue to move north, reflecting decidedly optimistic sentiment. Water Corp.’s Zacks Consensus Estimate for full-year 2017 has jumped from $7.03 a couple of months ago to $7.31 today, on the back of 13 upward estimate revisions versus none lower.
Ubiquiti Networks has a solid earnings surprise history for the trailing four quarters, having beaten estimates thrice, for an average beat of 13.3%.
Sonus Networks has a striking earnings surprise history for the trailing four quarters, beating estimates thrice for an average positive surprise of 57.6%.
Sierra Wireless has beaten estimates impressively thrice over the trailing four quarters, with an average positive surprise of 155.9%.
3 Top Picks to Ride the Hottest Tech Trend
Zacks just released a Special Report to guide you through a space that has already begun to transform our entire economy...
Last year, it was generating $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for those who make the right trades early. Download Report with 3 Top Tech Stocks >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Waters Corp., Andrews Alliance Ink Co-Marketing Agreement
Waters Corp. (WAT - Free Report) recently inked an agreement with Andrew Alliance, which will enable drug development scientists to access a semi-automated sample preparation approach for released N-glycan profiling and analysis by LC and LC-MS.
Per the agreement, Waters Corp. will integrate its existing Glycoworks RapiFluor-MS (RFMS) N-Glycan Kits with an Andrew pipetting robot. A huge number of protein therapeutics are presently in development, and consequently the demand for glycan analyses is growing exponentially. Thus, this semi-automated sample preparation approach will enable laboratories to cater to the huge demand for glycan profiling, with better accuracy and precision of LC and LC-MS results.
Biopharmaceutical companies, these days, need to deliver detailed structural information on glycans for regulatory approval. Since its launch in Feb 2015, RFMS N-Glycan Kit has benefited laboratories by providing simplified sample preparation at unprecedented speed and sensitivity. The combination of Waters and Andrew Alliance technologies makes it simpler and more efficient to scale up samples tested with the same enhanced optical, and MS sensitivity that users got the RapiFluor-MS labelling reagent.
Waters Corp. has been riding on strong momentum in its pharmaceutical business. Positive macro trends, including rising global regulatory standards, increasing access of patients to prescription drugs, growing testing needs of newer biological drugs and ever-increasing complexity in molecular structure, are acting as tailwinds for the pharmaceutical business. Its solid presence in the chromatography instrument and pharmaceuticals markets should generate enhanced profits, going forward.
The company recent share price performance also reflects these robust growth trends. Over the past six months, shares of Water Corp. recorded an average return of 35.9%, ahead of the Zacks Classified Instruments-Scientific industry average of 30%.
The analyst community is also feeling bullish about this Zacks Rank #2 (Buy) company as its earnings estimates continue to move north, reflecting decidedly optimistic sentiment. Water Corp.’s Zacks Consensus Estimate for full-year 2017 has jumped from $7.03 a couple of months ago to $7.31 today, on the back of 13 upward estimate revisions versus none lower.
Waters Corporation Price and Consensus
Waters Corporation Price and Consensus | Waters Corporation Quote
Other Stocks to Consider
Other similarly-ranked stocks in the broader computer & technology sector include Ubiquiti Networks, Inc. , Sonus Networks, Inc. and Sierra Wireless, Inc. . You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Ubiquiti Networks has a solid earnings surprise history for the trailing four quarters, having beaten estimates thrice, for an average beat of 13.3%.
Sonus Networks has a striking earnings surprise history for the trailing four quarters, beating estimates thrice for an average positive surprise of 57.6%.
Sierra Wireless has beaten estimates impressively thrice over the trailing four quarters, with an average positive surprise of 155.9%.
3 Top Picks to Ride the Hottest Tech Trend
Zacks just released a Special Report to guide you through a space that has already begun to transform our entire economy...
Last year, it was generating $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for those who make the right trades early. Download Report with 3 Top Tech Stocks >>